Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 6/20 | 0.63 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.63 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | CD69 | Q07108 | 1/20 | 0.53 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.48 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.48 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.47 |
| ▸ | FGF1 | P05230 | 1/20 | 0.45 |
| ▸ | FGF2 | P09038 | 1/20 | 0.45 |
| ▸ | VEGFA | P15692 | 1/20 | 0.45 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL34473199 | 0.98 | LGALS3 (0.62) | LGALS3LGALS8LGALS4MAPK1CD69 | |
| SCHEMBL17777302 | 0.98 | LGALS3 (0.62) | LGALS3LGALS8LGALS4MAPK1CD69 | |
| SCHEMBL19579354 | 0.98 | LGALS3 (0.62) | LGALS3LGALS8LGALS4MAPK1CD69 | |
| SCHEMBL6806201 | 0.98 | LGALS3 (0.62) | LGALS3LGALS8LGALS4MAPK1CD69 | |
| SCHEMBL6806198 | 0.98 | LGALS3 (0.62) | LGALS3LGALS8LGALS4MAPK1CD69 | |
| SCHEMBL29399861 | 0.98 | LGALS3 (0.62) | LGALS3LGALS8LGALS4MAPK1CD69 | |
| SCHEMBL18867406 | 0.98 | LGALS3 (0.62) | LGALS3LGALS8LGALS4MAPK1CD69 | |
| SCHEMBL17777288 | 0.97 | LGALS3 (0.59) | LGALS3LGALS8LGALS4MAPK1CD69 | |
| SCHEMBL30483911 | 0.97 | LGALS3 (0.59) | LGALS3LGALS8LGALS4MAPK1CD69 | |
| SCHEMBL19241971 | 0.97 | LGALS3 (0.64) | LGALS3LGALS8LGALS4MAPK1CD69 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118878651-A | Cell culture process for preparing glycoprotein | 里珍纳龙药品有限公司 | 2024-11-01 | — | — | CN | claimed |
| CN-110914293-B | Cell culture process for preparing glycoprotein | 里珍纳龙药品有限公司 | 2024-08-13 | — | — | CN | claimed |
| US-RE49192-E1 | Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile | INTERNATIONAL—DRUG—DEVELOPMENT BIOTECH (FR) | 2022-08-30 | — | — | US | claimed |
| CN-119639577-A | Engineered and fully-functionally tailored glycoproteins | 利玛泰克生物制品公司 | 2025-03-18 | — | — | CN | disclosed |
| CN-118878651-A | Cell culture process for preparing glycoprotein | 里珍纳龙药品有限公司 | 2024-11-01 | — | — | CN | disclosed |
| US-20240287568-A1 | Engineered and Fully-Functional Customized Glycoproteins | LIMMATECH BIOLOGICS AG (CH) | 2024-08-29 | — | — | US | disclosed |
| CN-110914293-B | Cell culture process for preparing glycoprotein | 里珍纳龙药品有限公司 | 2024-08-13 | — | — | CN | disclosed |
| US-11913051-B2 | Engineered and fully-functional customized glycoproteins | LIMMATECH BIOLOGICS AG (CH) | 2024-02-27 | — | — | US | disclosed |
| EP-3461843-B1 | ANTI-CD19 ANTIBODY HAVING ADCC AND CDC FUNCTIONS AND IMPROVED GLYCOSYLATION PROFILE | INT DRUG DEVELOPMENT BIOTECH (FR) | 2023-09-06 | — | — | EP | disclosed |
| US-RE49192-E1 | Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile | INTERNATIONAL—DRUG—DEVELOPMENT BIOTECH (FR) | 2022-08-30 | — | — | US | disclosed |
| EP-3967765-A1 | CELL CULTURE PROCESS FOR MAKING A GLYCOPROTEIN | FrieslandCampina Nederland B.V. (NL) | 2022-03-16 | — | — | EP | disclosed |
| CN-114075269-A | Cell culture process for the production of glycoproteins | 菲仕兰坎皮纳荷兰私人有限公司 | 2022-02-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240287568-A1 | Engineered and Fully-Functional Customized Glycoproteins | SIGLEC7, ENGASE, SIGLEC9 | LGALS3 49/4885LGALS8 34/4885LGALS4 25/4885 |
| US-11913051-B2 | Engineered and fully-functional customized glycoproteins | SIGLEC7, ENGASE, SIGLEC9 | LGALS3 49/4885LGALS8 34/4885LGALS4 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.